Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352429 | 0.80 | CYP3A4 (0.60) | SLC6A2SLC6A4SLC6A3FASN | |
| SCHEMBL6496581 | 0.79 | GRM2 (0.49) | GRM2SLC6A2SLC6A4SLC6A3CTRB1 | |
| SCHEMBL14486238 | 0.79 | GRM2 (0.49) | GRM2SLC6A2SLC6A4SLC6A3CTRB1 | |
| SCHEMBL11377847 | 0.77 | SIGMAR1 (0.66) | GRM2 | |
| SCHEMBL3142790 | 0.76 | LMNA (0.63) | — | |
| SCHEMBL12903280 | 0.76 | GLA (0.50) | GRM2 | |
| SCHEMBL28332415 | 0.76 | GRM2 (0.40) | GRM2SLC6A2SLC6A4SLC6A3CTRB1 | |
| SCHEMBL19066636 | 0.76 | ABCB1 (0.46) | GRM2CTRB1F2PRSS1FASN | |
| SCHEMBL7634585 | 0.76 | GRM2 (0.46) | GRM2SLC6A2SLC6A4SLC6A3CTRB1 | |
| SCHEMBL28330977 | 0.76 | CASP1 (0.47) | GRM2CTRB1F2PRSS1FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814360-B2 | Isocyanates, derivatives, and processes for producing the same | NOVOMER, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814498-B2 | Polylactone foams and methods of making the same | NOVOMER, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814498-B2 | Polylactone foams and methods of making the same | NOVOMER, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814360-B2 | Isocyanates, derivatives, and processes for producing the same | NOVOMER, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210324168-A1 | POLYLACTONE FOAMS AND METHODS OF MAKING THE SAME | NOVOMER, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210277028-A1 | METAL-ORGANIC FRAMEWORK CATALYSTS, AND USES THEREOF | NOVOMER, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210221762-A1 | SYSTEMS AND PROCESSES FOR PRODUCING ORGANIC ACIDS DIRECTLY FROM BETA-LACTONES | NOVOMER, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10961209-B2 | Processes for producing beta-lactone and beta-lactone derivatives with heterogenous catalysts | NOVOMER, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200331876-A1 | ISOCYANATES, DERIVATIVES, AND PROCESSES FOR PRODUCING THE SAME | NOVOMER, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10676426-B2 | Acrylonitrile derivatives from epoxide and carbon monoxide reagents | NOVOMER, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| CN-109414414-A | Method and composition for treating obesity and/or diabetes and for identifying candidate therapeutic agent | 戴维·格拉德斯通研究所 | 2019-03-01 | — | — | CN | disclosed |
| US-20190047972-A1 | PROCESSES FOR PRODUCING BETA-LACTONE AND BETA-LACTONE DERIVATIVES WITH HETEROGENOUS CATALYSTS | NOVOMER, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190002400-A1 | Acrylonitrile Derivatives from Epoxide and Carbon Monoxide Reagents | NOVOMER, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002293-A1 | Biobased Carbon Fibers and Carbon Black and Methods of Making the Same | NOVOMER, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2019006366-A1 | PROCESS FOR THE PREPARATION OF ORGANIC ACIDS FROM BETA LACTONES | NOVOMER, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| CN-1128819-C | Water soluble polymers and their use in cosmetic formulations | BASF AG (DE) | 2003-11-26 | — | — | CN | disclosed |
| US-6458348-B1 | Use of water-soluble polymers as biocides | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| EP-0915915-B1 | WATER SOLUBLE POLYMERS AND THEIR USE IN COSMETIC FORMULATIONS | BASF AG (DE) | 2001-10-31 | — | — | EP | disclosed |
| US-6271327-B1 | HYDROXYALKYLACRYLIC AMIDES AND DIHYDROXYALKYLACRYLIC IMIDE POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| CN-1232473-A | Water-soluble polymers and their use in cosmetic formulations | BASF AG (DE) | 1999-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676426-B2 | Acrylonitrile derivatives from epoxide and carbon monoxide reagents | POR, AGL, ALK | GRM2 4663/4885SLC6A2 4681/4885SLC6A4 3765/4885 |
| US-20200331876-A1 | ISOCYANATES, DERIVATIVES, AND PROCESSES FOR PRODUCING THE SAME | IDH1, IDH2, IDH3A | GRM2 4460/4885SLC6A2 4883/4885SLC6A4 4832/4885 |
| US-20190002293-A1 | Biobased Carbon Fibers and Carbon Black and Methods of Making the Same | AGL, CBR1, FASN | GRM2 4538/4885SLC6A2 4543/4885SLC6A4 4147/4885 |
| US-11814360-B2 | Isocyanates, derivatives, and processes for producing the same | IDH1, IDH2, IDH3A | GRM2 4460/4885SLC6A2 4883/4885SLC6A4 4832/4885 |
| US-20210277028-A1 | METAL-ORGANIC FRAMEWORK CATALYSTS, AND USES THEREOF | PPOX, PCCA, MCCC2 | GRM2 3200/4885SLC6A2 4880/4885SLC6A4 4785/4885 |
| US-20190002400-A1 | Acrylonitrile Derivatives from Epoxide and Carbon Monoxide Reagents | POR, AGL, ALK | GRM2 4663/4885SLC6A2 4681/4885SLC6A4 3765/4885 |
| US-10961209-B2 | Processes for producing beta-lactone and beta-lactone derivatives with heterogenous catalysts | AGL, HBZ, RIOX2 | GRM2 4050/4885SLC6A2 4857/4885SLC6A4 4779/4885 |
| US-20190047972-A1 | PROCESSES FOR PRODUCING BETA-LACTONE AND BETA-LACTONE DERIVATIVES WITH HETEROGENOUS CATALYSTS | AGL, HBZ, RIOX2 | GRM2 4050/4885SLC6A2 4857/4885SLC6A4 4779/4885 |
| US-20210221762-A1 | SYSTEMS AND PROCESSES FOR PRODUCING ORGANIC ACIDS DIRECTLY FROM BETA-LACTONES | AGL, FGB, COASY | GRM2 1924/4885SLC6A2 4837/4885SLC6A4 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.